REFERED TO FORMULA PIRIMIDINYL-PIRIDYLOXY-NAPHTIL COMPOUNDS (I ') WHERE R1, R2, R3, R4, R5, R6, R7 AND n ARE AS DEFINED IN THE DESCRIPTION. THEY ARE PREFERRED COMPOUNDS: (S) -3- (2-CIANOPROPAN-2-IL) -N- (6-METHYL-5 - ((3- (2- (PIPERIDIN-3-ILAMINO) PIRIMIDIN-4-IL) PIRIDIN -2-IL) OXI) NAFTALEN-1-IL) BENZAMIDE； (S) -1- (2-CHLOROPHENYL) -N- (2-FLUORO-6-METHYL-5 - ((3- (2- (PIPERIDIN-3-ILAMINO) PIRIMIDIN-4-IL) PIRIDIN-2-IL ) OXI) NAFTALEN-1-IL) METHANOSULFONAMIDE； AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. THESE COMPOUNDS HAVE A MODULATING ACTIVITY OF THE REQUIRING ENZYME OF INOSITOL 1 (IRE1) BEING USEFUL IN THE TREATMENT OF LUNG MICROCICTIC CANCER, ADENOCARCINOMA OF LUNGREFERIDO A COMPUESTOS PIRIMIDINIL-PIRIDILOXI-NAFTIL DE FORMULA (I') DONDE R1, R2, R3, R4, R5, R6, R7 Y n SON TAL COMO SE DEFINEN EN LA DESCRIPCION. SON COMPUESTOS PREFERIDOS: (S)-3-(2-CIANOPROPAN-2-IL)-N-(6-METIL-5-((3-(2-(PIPERIDIN-3-ILAMINO)PIRIMIDIN-4-IL)PIRIDIN-2-IL)OXI)NAFTALEN-1-IL)BENZAMIDA； (S)-1-(2-CLOROFENIL)-N-(2-FLUORO-6-METIL-5-((3-(2-(PIPERIDIN-3-ILAMINO)PIRIMIDIN-4-IL)PIRIDIN-2-IL)OXI)NAFTALEN-1-IL)METANOSULFONAMIDA； ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS TIENEN ACTIVIDAD DE MODULACION DE LA ENZIMA REQUIRENTE DE INOSITOL 1 (IRE1) SIENDO UTILES EN EL TRATAMIENTO DE CANCER MICROCITICO DE PULMON, ADENOCARCINOMA DE PULMON
